Before the varicella vaccine (Varivax) was released for use in 1995, nearly all of the 4 million children born each year in the United States contracted chickenpox, resulting in hospitalization in five of every 1,000 cases and 100 deaths.
It is not known whether the weakened virus used for VZV can remain dormant in the body, eventually causing shingles in the same way that the naturally occurring varicella virus can.
Chickenpox vaccine or varicella zoster vaccine (VZV) is an injection that protects children from contracting chickenpox (varicella), one of the most common childhood diseases.
Although children who have had chickenpox are immune to the disease and cannot contract it a second time, the varicella zoster virus can remain inactive in the human body.
A 2002 study indicated that exposure to varicella is much higher in adults living with children and that such exposure substantially boosts immunity against shingles.
However unlike other weakened viruses, varicella zoster remains in the cell rather than being secreted from the cell and collected from the culture medium.
Varivax-The brand name for varicella virus vaccine live, an immunizing agent used to prevent infection by the Herpes (Varicella) zoster virus.
Chickenpox (also called varicella) is a common, extremely infectious, rash-producing childhood disease that also affects adults on occasion.
Varicella (chickenpox vaccine)-Given by injection between the ages of 12-18 months or later for children who have not had chickenpox.
Prior to the use of the varicella vaccine, chickenpox was a typical part of growing up for most children in the industrialized world.